Unlu S, Sanchez Navarro B, Cakan E, Berchtold D, Meleka Hanna R, Vural S
Front Immunol. 2024; 15:1346671.
PMID: 38698867
PMC: 11063302.
DOI: 10.3389/fimmu.2024.1346671.
Carstens P, Mullar L, Wrede A, Zechel S, Wachowski M, Brandis A
Front Immunol. 2023; 14:1177721.
PMID: 37731487
PMC: 10508232.
DOI: 10.3389/fimmu.2023.1177721.
Fichtner M, Hoehn K, Ford E, Mane-Damas M, Oh S, Waters P
Acta Neuropathol Commun. 2022; 10(1):154.
PMID: 36307868
PMC: 9617453.
DOI: 10.1186/s40478-022-01454-0.
Sobieszczuk E, Szczudlik P, Kubiszewska J, Szyluk B, Lipowska M, Dutkiewicz M
Arch Immunol Ther Exp (Warsz). 2021; 69(1):22.
PMID: 34338918
PMC: 8328853.
DOI: 10.1007/s00005-021-00626-5.
Mantegazza R, Antozzi C
Front Neurol. 2020; 11:981.
PMID: 32982957
PMC: 7492201.
DOI: 10.3389/fneur.2020.00981.
Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology.
Fichtner M, Jiang R, Bourke A, Nowak R, OConnor K
Front Immunol. 2020; 11:776.
PMID: 32547535
PMC: 7274207.
DOI: 10.3389/fimmu.2020.00776.
New Pathways and Therapeutic Targets in Autoimmune Myasthenia Gravis.
Behin A, Le Panse R
J Neuromuscul Dis. 2018; 5(3):265-277.
PMID: 30010142
PMC: 6087460.
DOI: 10.3233/JND-170294.
Advances in autoimmune myasthenia gravis management.
Wang S, Breskovska I, Gandhy S, Punga A, Guptill J, Kaminski H
Expert Rev Neurother. 2018; 18(7):573-588.
PMID: 29932785
PMC: 6289049.
DOI: 10.1080/14737175.2018.1491310.
Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis.
Hewett K, Sanders D, Grove R, Broderick C, Rudo T, Bassiri A
Neurology. 2018; 90(16):e1425-e1434.
PMID: 29661905
PMC: 5902787.
DOI: 10.1212/WNL.0000000000005323.
Correlations of TNF-α gene promoter polymorphisms with the risk of thymoma-associated myasthenia gravis in a northern Chinese Han population.
Yang H, Lei P, Xie Y, Han Z, Li D, Wang S
Cancer Gene Ther. 2017; 24(6):259-266.
PMID: 28429750
DOI: 10.1038/cgt.2017.13.
Preconditioned mesenchymal stem cells treat myasthenia gravis in a humanized preclinical model.
Sudres M, Maurer M, Robinet M, Bismuth J, Truffault F, Girard D
JCI Insight. 2017; 2(7):e89665.
PMID: 28405609
PMC: 5374074.
DOI: 10.1172/jci.insight.89665.
Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome.
Lunde S, Kristoffersen E, Sapkota D, Risa K, Dahl O, Bruland O
PLoS One. 2016; 11(8):e0161226.
PMID: 27536947
PMC: 4990178.
DOI: 10.1371/journal.pone.0161226.
Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome.
Kannel K, Alnek K, Vahter L, Gross-Paju K, Uibo R, Kisand K
PLoS One. 2015; 10(11):e0143393.
PMID: 26600308
PMC: 4658115.
DOI: 10.1371/journal.pone.0143393.
Deleted in Breast Cancer 1 Suppresses B Cell Activation through RelB and Is Regulated by IKKα Phosphorylation.
Kong S, Dong H, Song J, Thiruppathi M, Prabhakar B, Qiu Q
J Immunol. 2015; 195(8):3685-93.
PMID: 26378077
PMC: 4642440.
DOI: 10.4049/jimmunol.1500713.
B Cell-Activating Factor. An Orchestrator of Lymphoid Follicles in Severe Chronic Obstructive Pulmonary Disease.
Polverino F, Cosio B, Pons J, Laucho-Contreras M, Tejera P, Iglesias A
Am J Respir Crit Care Med. 2015; 192(6):695-705.
PMID: 26073875
PMC: 4595676.
DOI: 10.1164/rccm.201501-0107OC.
Characterization of B cells in muscle-specific kinase antibody myasthenia gravis.
Guptill J, Yi J, Sanders D, Guidon A, Juel V, Massey J
Neurol Neuroimmunol Neuroinflamm. 2015; 2(2):e77.
PMID: 25745635
PMC: 4345633.
DOI: 10.1212/NXI.0000000000000077.
Intravenous Immunoglobulin and Immunomodulation of B-Cell - in vitro and in vivo Effects.
Mitrevski M, Marrapodi R, Camponeschi A, Cavaliere F, Lazzeri C, Todi L
Front Immunol. 2015; 6:4.
PMID: 25657650
PMC: 4302981.
DOI: 10.3389/fimmu.2015.00004.
VAV1 and BAFF, via NFκB pathway, are genetic risk factors for myasthenia gravis.
Avidan N, Le Panse R, Harbo H, Bernasconi P, Poulas K, Ginzburg E
Ann Clin Transl Neurol. 2014; 1(5):329-39.
PMID: 25356403
PMC: 4184684.
DOI: 10.1002/acn3.51.
Targeting dendritic cell function during systemic autoimmunity to restore tolerance.
Mackern-Oberti J, Vega F, Llanos C, Bueno S, Kalergis A
Int J Mol Sci. 2014; 15(9):16381-417.
PMID: 25229821
PMC: 4200801.
DOI: 10.3390/ijms150916381.
Silencing miR-146a influences B cells and ameliorates experimental autoimmune myasthenia gravis.
Zhang J, Jia G, Liu Q, Hu J, Yan M, Yang B
Immunology. 2014; 144(1):56-67.
PMID: 24962817
PMC: 4264910.
DOI: 10.1111/imm.12347.